Real-world effectiveness of Sotrovimab in patients infected with SARS-CoV-2 Omicron subvariant BA.2 in Western Sydney, Australia

Eric Kalo; Ziad Basyouni; Gideon Meyerowitz Katz; Vahid Karkvandi; Leanne Watson; Helen Crowther; Scott Read; Matthew V.N. O'Sullivan; Jasmin Ellis; Joanne Medlin; Golo Ahlenstiel

doi:10.1002/jmv.70235

Real-world effectiveness of Sotrovimab in patients infected with SARS-CoV-2 Omicron subvariant BA.2 in Western Sydney, Australia

Eric Kalo, Ziad Basyouni, Gideon Meyerowitz Katz, Vahid Karkvandi, Leanne Watson, Helen Crowther, Scott Read, Matthew V.N. O'Sullivan, Jasmin Ellis, Joanne Medlin, Golo Ahlenstiel

School of Medicine

Research output: Contribution to journal › Article › peer-review

Abstract

Laboratory-based findings suggest that Sotrovimab is significantly less effective against emerging CARS-CoV-2 variants, however, clinical data is lacking. Here we examined the effectiveness of sotrovimab, in preventing emergency department (ED) presentation and subsequent hospitalization in high-risk subgroups of patients during the SARS-CoV-2 Delta and Omicron waves in Western Sydney, Australia (n = 515). Risk for ED attendance was comparable in Omicron patients, whether BA.1 or BA.2, compared to Delta patients (hazard ratio of 0.97 [0.36-2.64]). These findings highlight the need for caution when using in vitro findings to drive clinical practice, especially when the consequence is to withhold potentially lifesaving treatment.

Original language	English
Article number	e70235
Number of pages	5
Journal	Journal of Medical Virology
Volume	97
Issue number	2
DOIs	https://doi.org/10.1002/jmv.70235
Publication status	Published - Feb 2025

Keywords

COVID-19
Delta
hospitalisation
monoclonal
Omicron BA.2
SARS-CoV-2
sotrovimab

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1002/jmv.70235Licence: CC BY

Full textFinal published version, 491 KBLicence: CC BY

Cite this

Kalo, E., Basyouni, Z., Katz, G. M., Karkvandi, V., Watson, L., Crowther, H., Read, S., O'Sullivan, M. V. N., Ellis, J., Medlin, J., & Ahlenstiel, G. (2025). Real-world effectiveness of Sotrovimab in patients infected with SARS-CoV-2 Omicron subvariant BA.2 in Western Sydney, Australia. Journal of Medical Virology, 97(2), Article e70235. https://doi.org/10.1002/jmv.70235

@article{ec1c0c7851604c15a7c9ab358a538bc8,

title = "Real-world effectiveness of Sotrovimab in patients infected with SARS-CoV-2 Omicron subvariant BA.2 in Western Sydney, Australia",

abstract = "Laboratory-based findings suggest that Sotrovimab is significantly less effective against emerging CARS-CoV-2 variants, however, clinical data is lacking. Here we examined the effectiveness of sotrovimab, in preventing emergency department (ED) presentation and subsequent hospitalization in high-risk subgroups of patients during the SARS-CoV-2 Delta and Omicron waves in Western Sydney, Australia (n = 515). Risk for ED attendance was comparable in Omicron patients, whether BA.1 or BA.2, compared to Delta patients (hazard ratio of 0.97 [0.36-2.64]). These findings highlight the need for caution when using in vitro findings to drive clinical practice, especially when the consequence is to withhold potentially lifesaving treatment.",

keywords = "COVID-19, Delta, hospitalisation, monoclonal, Omicron BA.2, SARS-CoV-2, sotrovimab",

author = "Eric Kalo and Ziad Basyouni and Katz, {Gideon Meyerowitz} and Vahid Karkvandi and Leanne Watson and Helen Crowther and Scott Read and O'Sullivan, {Matthew V.N.} and Jasmin Ellis and Joanne Medlin and Golo Ahlenstiel",

year = "2025",

month = feb,

doi = "10.1002/jmv.70235",

language = "English",

volume = "97",

journal = "Journal of Medical Virology",

issn = "0146-6615",

publisher = "John Wiley and Sons Inc",

number = "2",

}

TY - JOUR

T1 - Real-world effectiveness of Sotrovimab in patients infected with SARS-CoV-2 Omicron subvariant BA.2 in Western Sydney, Australia

AU - Kalo, Eric

AU - Basyouni, Ziad

AU - Katz, Gideon Meyerowitz

AU - Karkvandi, Vahid

AU - Watson, Leanne

AU - Crowther, Helen

AU - Read, Scott

AU - O'Sullivan, Matthew V.N.

AU - Ellis, Jasmin

AU - Medlin, Joanne

AU - Ahlenstiel, Golo

PY - 2025/2

Y1 - 2025/2

N2 - Laboratory-based findings suggest that Sotrovimab is significantly less effective against emerging CARS-CoV-2 variants, however, clinical data is lacking. Here we examined the effectiveness of sotrovimab, in preventing emergency department (ED) presentation and subsequent hospitalization in high-risk subgroups of patients during the SARS-CoV-2 Delta and Omicron waves in Western Sydney, Australia (n = 515). Risk for ED attendance was comparable in Omicron patients, whether BA.1 or BA.2, compared to Delta patients (hazard ratio of 0.97 [0.36-2.64]). These findings highlight the need for caution when using in vitro findings to drive clinical practice, especially when the consequence is to withhold potentially lifesaving treatment.

AB - Laboratory-based findings suggest that Sotrovimab is significantly less effective against emerging CARS-CoV-2 variants, however, clinical data is lacking. Here we examined the effectiveness of sotrovimab, in preventing emergency department (ED) presentation and subsequent hospitalization in high-risk subgroups of patients during the SARS-CoV-2 Delta and Omicron waves in Western Sydney, Australia (n = 515). Risk for ED attendance was comparable in Omicron patients, whether BA.1 or BA.2, compared to Delta patients (hazard ratio of 0.97 [0.36-2.64]). These findings highlight the need for caution when using in vitro findings to drive clinical practice, especially when the consequence is to withhold potentially lifesaving treatment.

KW - COVID-19

KW - Delta

KW - hospitalisation

KW - monoclonal

KW - Omicron BA.2

KW - SARS-CoV-2

KW - sotrovimab

UR - http://www.scopus.com/inward/record.url?scp=85217767964&partnerID=8YFLogxK

U2 - 10.1002/jmv.70235

DO - 10.1002/jmv.70235

M3 - Article

AN - SCOPUS:85217767964

SN - 0146-6615

VL - 97

JO - Journal of Medical Virology

JF - Journal of Medical Virology

IS - 2

M1 - e70235

ER -

Real-world effectiveness of Sotrovimab in patients infected with SARS-CoV-2 Omicron subvariant BA.2 in Western Sydney, Australia

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this